MRES: AI 评分 42/100 — AI 分析 (4月 2026)

Institute of Biomedical Research Corp. operates in the healthcare sector, providing biomedical research and analytical services internationally. The company focuses on developing and commercializing biomedical products, diagnostic methods, and environmental solutions.

Key Facts: AI Score: 42/100 Sector: Healthcare

公司概况

概要：

Institute of Biomedical Research Corp., based in Montenegro, offers biomedical research, analytical services, and product development. The company focuses on regulatory compliance, environmental surveillance, and creating innovative healthcare solutions. With a global reach, including a Canadian office, it serves the biotechnology sector through diverse research and product offerings.

MRES是做什么的？

Founded in 2010, Institute of Biomedical Research Corp. is a biotechnology company based in Podgorica, Montenegro, with a representative office in Montreal, Canada. The company provides a range of biomedical research and analytical services both domestically and internationally. Its core activities encompass regulatory control of industrial activities and products, scientific surveillance of the living environment, and research and development of biomedical products and technologies. The company also focuses on regulatory evaluation and certification of biomedical products, fundamental scientific research, and the development of new diagnostic methods and experimental medical treatments. Institute of Biomedical Research Corp. researches and develops new biomedical and food products, offering graduate research programs in biomedical and environmental fields. The company provides a variety of healthcare devices, including analog NMS, digital muscle stimulators, and ultrasound devices. It also develops and commercializes microbicidal agents, disinfectant products, and various specialized products like bandages for burns, insecticides, and microbicidal towels. Further, the company offers services such as quality control, regulatory consulting, healthcare solutions, environmental analysis, building decontamination, and environmental protection and management. It also provides regulatory certifications for new biomedical products. The company's innovations include Purilair, a device for sterilizing compressed air in medical instruments, colloidal silver products, electro medical devices, and BioStim INF, used for edema reduction and pain relief.

MRES的投资论点是什么？

Institute of Biomedical Research Corp. operates in a niche segment of the biotechnology industry, focusing on biomedical research, analytical services, and specialized product development. With a market capitalization of $0.01 billion and a negative P/E ratio of -26.31, the company's financial performance reflects challenges in achieving profitability, indicated by a profit margin of -588.7%. However, a gross margin of 38.4% suggests potential in its core operations. Growth catalysts include expanding its regulatory and environmental service offerings, as well as commercializing its range of biomedical products. Key risks involve achieving sustainable profitability and navigating regulatory hurdles in international markets.

MRES在哪个行业运营？

Institute of Biomedical Research Corp. operates within the global biotechnology industry, which is characterized by rapid innovation, stringent regulatory requirements, and intense competition. The company's focus on biomedical research, analytical services, and specialized product development positions it within a niche segment of the market. Key trends in the industry include the increasing demand for personalized medicine, the growing importance of regulatory compliance, and the rise of environmental concerns. Competitors include companies like BBIXF, CAAOF, CHOOF, CLYYF, and ELVAF, which operate in similar areas of biomedical research and product development.

Biotechnology

Healthcare

MRES有哪些增长机遇？

Expanding Regulatory and Environmental Services: Institute of Biomedical Research Corp. can capitalize on the growing demand for regulatory compliance and environmental services. By offering specialized services in regulatory certifications and environmental analysis, the company can attract clients seeking to navigate complex regulatory landscapes. The market for environmental services is projected to reach $1.2 trillion by 2027, presenting a significant growth opportunity.
Commercializing Biomedical Products: The company has the potential to drive revenue growth by commercializing its range of biomedical products, including microbicidal agents, disinfectant products, and healthcare devices. Focusing on niche markets and specialized applications can help the company differentiate its products and capture market share. The global market for medical devices is expected to reach $600 billion by 2025.
Developing New Diagnostic Methods: Investing in the development of new diagnostic methods and experimental medical treatments can position the company as an innovator in the biotechnology sector. By focusing on unmet medical needs and emerging technologies, the company can attract research funding and partnerships. The market for diagnostic testing is projected to reach $115 billion by 2028.
Geographic Expansion: Expanding its geographic reach beyond Montenegro and Canada can open up new markets and revenue streams. Targeting regions with growing healthcare sectors and unmet medical needs can help the company diversify its operations and reduce its reliance on domestic markets. Emerging markets in Asia and Latin America offer significant growth potential.
Strategic Partnerships: Forming strategic partnerships with other companies in the biotechnology sector can provide access to new technologies, markets, and resources. Collaborating with research institutions, pharmaceutical companies, and healthcare providers can accelerate product development and commercialization. Strategic alliances can also help the company expand its capabilities and enhance its competitive position.

Market capitalization of $0.01 billion reflects its small size within the biotechnology sector.
Negative P/E ratio of -26.31 indicates the company is currently not profitable.
Profit margin of -588.7% highlights significant challenges in achieving profitability.
Gross margin of 38.4% suggests potential in its core operations despite overall losses.
Beta of 0.04 indicates low volatility relative to the market.

MRES提供哪些产品和服务？

Provides regulatory control of industrial activities and products.
Conducts scientific surveillance of the living environment.
Engages in research and development of biomedical products and technologies.
Offers regulatory evaluation and certification of biomedical products.
Conducts fundamental scientific research.
Develops new diagnostic methods and experimental medical treatments.
Researches and develops new biomedical and food products.
Provides programs for graduate research studies in biomedical and environmental fields.

MRES如何赚钱？

Provides biomedical research and analytical services to various industries.
Develops and commercializes biomedical products and technologies.
Offers regulatory evaluation and certification services for biomedical products.
Generates revenue through the sale of healthcare devices and specialized products.

Industrial companies requiring regulatory control and compliance.
Healthcare providers seeking advanced diagnostic methods and treatments.
Research institutions and universities involved in biomedical research.
Government agencies responsible for environmental surveillance and protection.

Specialized Expertise: Deep expertise in biomedical research, regulatory compliance, and environmental analysis.
Proprietary Technologies: Development and commercialization of unique biomedical products and technologies.
Regulatory Certifications: Ability to provide regulatory certifications for new biomedical products.
Established Presence: Long-standing presence in Montenegro with a growing international footprint.

什么因素可能推动MRES股价上涨？

Ongoing: Expansion of regulatory and environmental service offerings.
Upcoming: Commercialization of new biomedical products in international markets.
Ongoing: Development of new diagnostic methods and experimental treatments.
Upcoming: Strategic partnerships with research institutions and healthcare providers.

MRES的主要风险是什么？

Ongoing: Low profitability and negative profit margins.
Potential: Limited market capitalization and financial resources.
Ongoing: Dependence on niche markets and specialized applications.
Potential: OTC market listing may limit investor access and liquidity.
Potential: Intense competition in the biotechnology sector.

MRES的核心优势是什么？

Diverse range of biomedical research and analytical services.
Development and commercialization of specialized biomedical products.
Expertise in regulatory compliance and environmental analysis.
Established presence in Montenegro with international reach.

MRES的劣势是什么？

Low profitability and negative profit margins.
Limited market capitalization and financial resources.
Dependence on niche markets and specialized applications.
OTC market listing may limit investor access and liquidity.

MRES有哪些机遇？

Expanding regulatory and environmental service offerings.
Commercializing biomedical products in new markets.
Developing new diagnostic methods and experimental treatments.
Forming strategic partnerships with other companies and institutions.

MRES面临哪些威胁？

Intense competition in the biotechnology sector.
Stringent regulatory requirements and compliance costs.
Economic downturns and market volatility.
Technological advancements and disruptive innovations.

MRES的竞争对手是谁？

BioBrix Therapeutics Inc — Focuses on developing innovative therapies for cancer and other diseases. — (BBIXF)
CannAssist Africa Inc — Specializes in cannabis-based products for medical and wellness applications. — (CAAOF)
CHO Power AS — Develops and operates waste-to-energy plants using gasification technology. — (CHOOF)
Calyxt Inc — Focuses on developing plant-based products for food and industrial applications. — (CLYYF)
Elival Therapeutics Ltd — Develops innovative therapies for infectious diseases and cancer. — (ELVAF)

Key Metrics

MoonshotScore: 42/100

Company Profile

CEO: Drasko D. Pekovic
Headquarters: Podgorica, ME
Founded: 2004

AI Insight

AI analysis pending for MRES

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Institute of Biomedical Research Corp. do?

Institute of Biomedical Research Corp. provides biomedical research and analytical services, focusing on regulatory control, environmental surveillance, and product development. The company researches and develops biomedical and food products, offers graduate research programs, and provides healthcare devices. It also develops and commercializes microbicidal agents, disinfectant products, and specialized products like bandages for burns and insecticides, serving industrial companies, healthcare providers, and research institutions.

What do analysts say about MRES stock?

As of March 16, 2026, there is no available analyst coverage for Institute of Biomedical Research Corp. (MRES). Given its OTC listing and small market capitalization of $0.01 billion, the stock may not be widely followed by analysts. Key valuation metrics include a negative P/E ratio of -26.31 and a profit margin of -588.7%, reflecting challenges in achieving profitability. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.

What are the main risks for MRES?

The main risks for Institute of Biomedical Research Corp. include low profitability and negative profit margins, limited market capitalization and financial resources, dependence on niche markets and specialized applications, and the potential limitations of its OTC market listing. Intense competition in the biotechnology sector, stringent regulatory requirements, and economic downturns also pose significant risks. Investors should carefully consider these factors before investing in MRES.